Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Change in Cash (2016 - 2025)

Historic Change in Cash for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • Ernexa Therapeutics' Change in Cash rose 4753.83% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 7222.73%. This contributed to the annual value of -$9.9 million for FY2024, which is 15680.7% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Change in Cash of -$1.3 million as of Q3 2025, which was up 4753.83% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Change in Cash ranged from a high of $6.8 million in Q1 2021 and a low of -$6.2 million during Q3 2022
  • Moreover, its 5-year median value for Change in Cash was -$1.8 million (2024), whereas its average is -$447375.0.
  • Per our database at Business Quant, Ernexa Therapeutics' Change in Cash soared by 53321.3% in 2021 and then tumbled by 19284.73% in 2023.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Change in Cash stood at $6.8 million in 2021, then plummeted by 66.27% to $2.3 million in 2022, then skyrocketed by 32.23% to $3.0 million in 2023, then crashed by 183.83% to -$2.5 million in 2024, then surged by 49.98% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $2.4 million for Q2 2025, and $189000.0 during Q1 2025.